Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

891
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
891
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.0K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.0K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.0K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.0K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Clinical Outcomes and Predictors of Retinal Breaks in Patients With Vitreous Hemorrhage Secondary to a Posterior Vitreous Detachment.

Journal of vitreoretinal diseases·2026
Same author

Corrigendum to "Oculomics and AI: The eye as a biomarker for health span" [Asia-Pac J Ophthalmol 15 (1) (2026) 100282].

Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)·2026
Same author

RPE With ROCK-Mediated Epithelial-Mesenchymal Transition as a Key Contributor of Subretinal Fibrosis in AMD.

Investigative ophthalmology & visual science·2026
Same author

Comparability of aflibercept biosimilar with reference aflibercept in diabetic macular edema: subgroup analysis of the pivotal Phase-III INSIGHT randomized clinical trial.

Expert opinion on biological therapy·2026
Same author

Lipemia Retinalis as a Masquerader of Multiple Myeloma.

Retina (Philadelphia, Pa.)·2026
Same author

Aberrant retinal structure and vasculature in mouse models of dominant retinopathies caused by <i>CRX</i> homeodomain mutations.

bioRxiv : the preprint server for biology·2026
Same journal

Co-option of lysosomal machinery shapes the evolution of the intracellular photosymbiosis supporting coral reefs.

Cell·2026
Same journal

LEF1 and niche factors determine T cell stemness across chronic diseases.

Cell·2026
Same journal

Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders.

Cell·2026
Same journal

Four-dimensional molecular mapping from a spatial snapshot reveals the dynamics of hair follicle organogenesis.

Cell·2026
Same journal

Whole-cell particle-based digital twin simulations from 4D lattice light-sheet microscopy data.

Cell·2026
Same journal

Systematic discovery of pathogen effector functions across human pathogens and pathways.

Cell·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Dec 25, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.6K

Reducción de la carga del tratamiento en la DMAE

Rajendra S Apte1

  • 1Paul A. Cibis Distinguished Professor, Washington University in St. Louis School of Medicine, St. Louis, MO, USA.

Cell
|March 24, 2020
PubMed
Resumen
Este resumen es generado por máquina.

Los antagonistas del factor de crecimiento endotelial vascular-A (VEGF-A) ofrecen una nueva esperanza para la degeneración macular relacionada con la edad húmeda (AMD). Brolucizumab muestra resultados visuales comparables y mejores resultados anatómicos que aflibercept, reduciendo la carga del tratamiento.

Más Videos Relacionados

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
06:16

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies

Published on: July 28, 2023

3.0K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.4K

Videos de Experimentos Relacionados

Last Updated: Dec 25, 2025

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report
10:24

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

10.6K
Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies
06:16

Author Spotlight: Unraveling the Pathogenesis of Age-Related Macular Degeneration and Discovering Potential Therapies

Published on: July 28, 2023

3.0K
Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization
05:14

Author Spotlight: Overcoming Anti-VEGF Resistance Through Advanced Vascular Morphology Assessment in Choroidal Neovascularization

Published on: August 11, 2023

1.4K

Área de la Ciencia:

  • Oftalmología
  • Investigaciones médicas
  • Desarrollo de drogas

Sus antecedentes:

  • Los antagonistas del factor de crecimiento endotelial vascular-A (VEGF-A) han transformado el tratamiento de la degeneración macular relacionada con la edad.
  • La DMAE húmeda persistente requiere inyecciones intraoculares frecuentes, lo que supone una carga de tratamiento significativa.

Objetivo del estudio:

  • Comparar la eficacia de brolucizumab, un inhibidor directo del VEGF-A, con la de aflibercept en el tratamiento de la DMAE húmeda.
  • Evaluar los resultados visuales y anatómicos, incluida la reducción del líquido retiniano.

Principales métodos:

  • El brolucizumab inhibe directamente el VEGF-A.
  • Comparación de la agudeza visual y las mediciones del líquido retiniano entre los grupos tratados con brolucizumab y aflibercept.

Principales resultados:

  • Brolucizumab demostró resultados visuales comparables a los de aflibercept.
  • Los resultados anatómicos, específicamente la reducción del líquido retiniano, favorecieron al brolucizumab.

Conclusiones:

  • El brolucizumab representa una opción terapéutica prometedora para la DMAE húmeda.
  • La inhibición directa del VEGF-A con brolucizumab puede ofrecer un mejor control anatómico y reducir potencialmente la carga del tratamiento.